Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age20-70
SponsorChang-Ik Yoon

About this trial

This study aims to evaluate the impact of using propranolol, a non-selective beta-blocker, on preventing myocardial injury after non-cardiac surgery (MINS) in breast cancer patients who also have hypertension or angina. Stress from surgery and anesthesia can increase sympathetic activity and inflammation, which may lead to heart stress. This pragmatic clinical trial will compare patients who are prescribed propranolol as part of their routine care with those who are not. Researchers will analyze blood samples and surgical tissues collected during normal treatment to observe changes in heart health and the tumor microenvironment.

Eligibility criteria

Qualifiers

Female patients aged 20 to 70 years.

Patients diagnosed with hypertension or angina who require medication.

Patients diagnosed with unilateral, resectable primary breast cancer (ICD-10: C50), Stage I-III.

ECOG performance status of 0-1.

Disqualifiers

Patients with distant metastases.

Patients with active infectious diseases, autoimmune diseases (including specific rheumatic diseases), coagulation disorders, or cardiovascular diseases other than hypertension or angina pectoris.

Platelets <100,000/mm3

Hb <9 g/dL

Trial design

Treatments tested in this trial

  • propranolol
  • Usual Care

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Chang-Ik Yoon

Lead sponsor

Seoul St. Mary's Hospital

Sponsor institution

Seoul St. Mary's Hospital

Collaborator